Analysts think ASMB stock price could increase by 95%
Jun 07, 2025, 11:25 AM
6.49%
What does ASMB do
Assembly Biosciences, a biotechnology company based in South San Francisco, develops treatments for chronic hepatitis B and other infectious diseases, with a pipeline including multiple antiviral agents. The company, which went public in December 2010, employs 65 people.
5 analysts think ASMB stock price will increase by 95.49%. The current median analyst target is $31.62 compared to a current stock price of $16.18. The lowest analysts target is $29.29 and the highest analyst target is $36.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
